Faculty Profile
Dr. Jamieson
Catriona Jamieson, M.D., Ph.D.
Assistant Professor of Medicine
Division of Hematology-Oncology
Director for Stem Cell Research,
Moores UCSD Cancer Center
Office Address:
Division of Hematology-Oncology
University of California
Moores UCSD Cancer Center, MC-0987
3855 Health Sciences Drive
La Jolla, CA 92093
cjamieson@ucsd.edu
Office: ( 858) 534-7128
FAX: (858) 822-5399
Education and Training
| BS | Biology-Genetics, University of British Columbia | 1987 |
| Ph.D. | Microbiology, University of British Columbia | 1992 |
| MD | University of British Columbia | 1995 |
| Resident | University of British Columbia | 1995-1998 |
| Fellow, Bone Marrow Transplant | University of British Columbia |
1998 |
| Fellow, Bone Marrow Transplant | Stanford University |
1999-2002 |
| Postdoctoral Research Fellow | Stanford University |
2002-2005 |
Research Interests
Dr. Jamieson specialized in myeloproliferative disorders (MPDs) and leukemia. Myeloproliferative neoplasms are a family of uncommon but not rare degenerative disorders in which the body overproduces blood cells. Myeloproliferative neoplasms can cause many forms of blood clotting including heart attack, stroke, deep venous thrombosis, and pulmonary emboli and can develop into acute myelogenous leukemia. Although some effective treatments are available, they are laden with serious side effects. In addition, individuals can become resistant to the treatments. Dr. Jamieson studies the mutant stem cells and progenitor cells in myeloproliferative neoplasms. These cells can give rise to cancer stem cells. Cancer stem cells may lie low to evade chemotherapy and then activate again later, causing disease progression and resistance to treatment. Her goal is to find more selective, less toxic therapies. In the past two years, Dr. Jamieson’s stem-cell research studies have taken a great leap: from identifying a promising treatment in the laboratory to opening and completing the first clinical trial to target cancer stem cells in humans. This trial is the result of teamwork that has brought together her discoveries in myeloproliferative neoplasms and a local pharmaceutical company’s drug development track.
Publications
Jamieson CHM, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL. (2006) The JAK2 V617F mutation occursz in cells with hematopoietic stem cell phenotype and predisposes toward erythroid differentiation in polycythemia vera. Proceedings of the National Academic of Sciences USA 103:6224-6229.
Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebal J, Decesare S, Jovin T, Zafonte R, Lebowitz J, Flickinger JC, Tong D, Marks MP, Jamieson C, Luu D, Bell-Stephens T, Teraoka J (2005) Neutrotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial. J Neurosurg 103:38-45
Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer Stem Cells—Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells (2006) Cancer Res. 66:9339-9334.
Kavalerchik E, Goff D, Jamieson CHM. Cancer Stem Cells and CML. Jour of Clinical Oncology, 2008 (in press).
Rossi DJ, Jamieson, Weissman IL. Stem cells and the pathways to aging and cancer (2008) Cell 132(4):681-96.
Geron I, Abrahamsson AE, Barroga CF, Kavalerchik E, Gotlib J, Hood JD, Durocher J, Mak CC, Noronha G, Soll RM, Tefferi A, Kaushansky K. Jamierson CH. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. (2008) Cancer Cell, 13:321-330.
Cross NCP, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D. Radich J. Skoda R, Souverini S, Vainchenker W, Werstovsek S, Villeval J-L, Goldman JM. BCR-ABL2-positive and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features, Leukemia, 2008 (in press).
Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC, Young DJ, Naoe T, Murre, C, Jamieson CHM, Wang JYJ. Transformation of E2A-deficient pluripotent progenitors by BCR-ABL generates leukemia stem cells in the GMP compartment. Proceedings of the National Academy of Sciences USA, 2008 (in press).
Laboratory
|
||
Laboratory Personnel
|
||
| Name | Title | Laboratory Focus |
| Annelie Abrahamsson, MS | Staff Res Assoc | Leukemia Stem Cell (LSC) inhibition with targeted self-renewal pathway inhibitors. |
| Jennifer Alyono, BS | MSPT Student | Humanized mouse models of malaria. |
| Larissa Balaian, Ph.D. | Project Scientist | Transcription facult profiling in hESC. |
| Charlene Barroga, Ph.D. | Asst Project Scientist | Mechanisms of lineage priming in MPDs. |
| Kim-Hien Dao, DO, Ph.D. | Fellow | Generation of human MPD stem cells from hESC. |
| Ifat Geron | Graduate Student | MicroRNA regulation of Splicing in MPDs. |
| Daniel Goff, BS | MSTP Student | Survival pathway deregulation in CML. |
| Edward Kavalerchik, MD | Fellow | Generation of cancer stem cells from human ES cells (hESC). |
| Wen Ma, MD, Ph.D. | Project Scientist | Humanized mouse model of T-ALL. |
| Isabel Newton, MD, Ph.D. | Radiology Resident | Molecular imaging of LSC/NIH. |
| Christin Wu, Ph.D. | Project Scientist | Humanized mouse model of multiple melanoma. |
[text here] 